CA2587928A1 - Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites - Google Patents
Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites Download PDFInfo
- Publication number
- CA2587928A1 CA2587928A1 CA002587928A CA2587928A CA2587928A1 CA 2587928 A1 CA2587928 A1 CA 2587928A1 CA 002587928 A CA002587928 A CA 002587928A CA 2587928 A CA2587928 A CA 2587928A CA 2587928 A1 CA2587928 A1 CA 2587928A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- compound
- oxides
- tautomers
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000697 serotonin reuptake Effects 0.000 title abstract description 10
- 102000004980 Dopamine D2 Receptors Human genes 0.000 title abstract description 9
- 108090001111 Dopamine D2 Receptors Proteins 0.000 title abstract description 9
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 150000001204 N-oxides Chemical class 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000012886 Vertigo Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 230000016571 aggressive behavior Effects 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 231100000889 vertigo Toxicity 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000009977 dual effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 hydrochloric acid Chemical class 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- MECRKILGNPUEFQ-UHFFFAOYSA-N o-(2-aminoethyl)hydroxylamine Chemical compound NCCON MECRKILGNPUEFQ-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229940127333 Dopamine D2 Antagonists Drugs 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- QJULELIONYLITF-UHFFFAOYSA-N 1-(2-propan-2-yloxyphenyl)piperazine Chemical compound CC(C)OC1=CC=CC=C1N1CCNCC1 QJULELIONYLITF-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- WSQLCFKGZQTNOI-UHFFFAOYSA-N 4-chloro-1-[4-(trifluoromethyl)phenyl]butan-1-one Chemical compound FC(F)(F)C1=CC=C(C(=O)CCCCl)C=C1 WSQLCFKGZQTNOI-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- BPLWZJOHNMZAKP-UHFFFAOYSA-N 6-chloro-1-[4-(trifluoromethyl)phenyl]hexan-1-one Chemical compound FC(F)(F)C1=CC=C(C(=O)CCCCCCl)C=C1 BPLWZJOHNMZAKP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003170 musculotropic effect Effects 0.000 description 1
- ZEIPAQOMPRPQJR-UHFFFAOYSA-N o-[2-(methylamino)ethyl]hydroxylamine Chemical compound CNCCON ZEIPAQOMPRPQJR-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
Abstract
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula ( 1 ) wherein the symbols have the meanings given in the specification.
Description
PHENYLPIPERAZINES WITH A COMBINATION OF AFFINITY FOR DOPAMINE -The present invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity f or dopamine-receptors and to methods for the preparation of these compounds. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition.
More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of disorders in which dopamine-D2 receptors and serotonin reuptake sites are involved, or that can be treated via manipulation of those targets.
Phenylpiperazine derivatives with a dual action as dopamine-D2 antagonists and serotonin reuptake inhibitors are known from WO 01/014330. This combination is useful for the treatment of schizophrenia and other psychotic disorders which enables a more complete treatment of all disease symptoms (e.g. positive symptoms and negative symptoms).
In patent specification GB 1 378 080 (1974) oxime derivatives of halophenyl piperazinyl-alkyl ketones have been disclosed that posses useful pharmacological activity, especially as analgesic agents, anti-inflammatory agents and musculotropic spasmolytic agents.
The goal of the present invention was to provide further compounds with a dual action as dopamine-D2 antagonists and serotonin reuptake inhibitors.
The invention relates to compounds of the general formula (1):
I
N Q
R~
a L m 0 n N
N
~ (1) (R2)x wherein:
- m and n independently are either 1, 2, 3, 4, 5, 6, 7 or 8, - xis0, 1,2or3 - R2 is halogen, branched or unbranched alkyl(C,_6), phenyl, benzyl, branched or unbranched alkoxy(C,_s), trifluoromethyl or cyano - R3 and R4 independently represent hydrogen, alkyl (C,_s), phenyl, benzyl or acetyl - group Q is chosen from structural fragments A-N
O OH O OH
O~ ~ O J I / O I
A H B C D
N N
~ 1 >~O 0 I~~O O~
1 ~
E F G N
17~ O CI O) H J H K
(R1) N /O N O
O~
L M N
wherein:
- yisl,2or3 - R, is halogen, branched or unbranched alkyl(C,_s), phenyl, benzyl, branched or unbranched alkoxy(C,_6), trifluoromethyl or cyano, and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of disorders in which dopamine-D2 receptors and serotonin reuptake sites are involved, or that can be treated via manipulation of those targets.
Phenylpiperazine derivatives with a dual action as dopamine-D2 antagonists and serotonin reuptake inhibitors are known from WO 01/014330. This combination is useful for the treatment of schizophrenia and other psychotic disorders which enables a more complete treatment of all disease symptoms (e.g. positive symptoms and negative symptoms).
In patent specification GB 1 378 080 (1974) oxime derivatives of halophenyl piperazinyl-alkyl ketones have been disclosed that posses useful pharmacological activity, especially as analgesic agents, anti-inflammatory agents and musculotropic spasmolytic agents.
The goal of the present invention was to provide further compounds with a dual action as dopamine-D2 antagonists and serotonin reuptake inhibitors.
The invention relates to compounds of the general formula (1):
I
N Q
R~
a L m 0 n N
N
~ (1) (R2)x wherein:
- m and n independently are either 1, 2, 3, 4, 5, 6, 7 or 8, - xis0, 1,2or3 - R2 is halogen, branched or unbranched alkyl(C,_6), phenyl, benzyl, branched or unbranched alkoxy(C,_s), trifluoromethyl or cyano - R3 and R4 independently represent hydrogen, alkyl (C,_s), phenyl, benzyl or acetyl - group Q is chosen from structural fragments A-N
O OH O OH
O~ ~ O J I / O I
A H B C D
N N
~ 1 >~O 0 I~~O O~
1 ~
E F G N
17~ O CI O) H J H K
(R1) N /O N O
O~
L M N
wherein:
- yisl,2or3 - R, is halogen, branched or unbranched alkyl(C,_s), phenyl, benzyl, branched or unbranched alkoxy(C,_6), trifluoromethyl or cyano, and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
Prodrugs of the compounds mentioned above are in the scope of the present invention. Prodrugs are therapeutic agents which are inactive per se but are transformed into one or more active metabolites. Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule. These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Medicinal Chemistry: Principles and Practice, 1994, ISBN 0-85186-494-5, Ed.: F. D. King, p.
215; J. Stella, "Prodrugs as therapeutics", Expert Opin. Ther. Patents, 14(3), 280, 2004; P. Ettmayer et al., "Lessons learned from marketed and investigational prodrugs", J.Med.Chem., 47, 2393-2404, 2004). Pro-drugs, i.e. compounds which when administered to humans by any known route, are metabolised to compounds having formula (1), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups. Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hyd roxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
N-oxides of the compounds mentioned above are in the scope of the present invention. Tertiary amines may or may not give rise to N-oxide metabolites.
The extend to what N-oxidation takes place varies from trace amounts to a near quantitative conversion. N-oxides may be more active than their corresponding tertiary amines or less active. Whilst N-oxides are easily reduced to their corresponding tertiary amines by chemical means, in the human body this happens to varying degrees. Some N-oxides undergo nearly quantitative reductive conversion to the corresponding tertiary amines, in other cases the conversion is a mere trace reaction or even completely absent. (M.H. Bickel: "The pharmacology and Biochemistry of N-oxides", Pharmaco-loaical Reviews, 21(4), 325 - 355, 1969).
Preferred compounds of the invention are compounds having formula (I) wherein m is 1, n is 2, 3, 4 or 5, x is 1, R2 is 4-fluoro or 4-trifluoromethyl, R3 and independently represent hydrogen or methyl, group Q is chosen from structural fragments A, D, F or N, y is 1, and R, is branched or unbranched alkoxy(C,_3), and tautomers, stereoisomers a nd N -oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
215; J. Stella, "Prodrugs as therapeutics", Expert Opin. Ther. Patents, 14(3), 280, 2004; P. Ettmayer et al., "Lessons learned from marketed and investigational prodrugs", J.Med.Chem., 47, 2393-2404, 2004). Pro-drugs, i.e. compounds which when administered to humans by any known route, are metabolised to compounds having formula (1), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups. Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hyd roxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
N-oxides of the compounds mentioned above are in the scope of the present invention. Tertiary amines may or may not give rise to N-oxide metabolites.
The extend to what N-oxidation takes place varies from trace amounts to a near quantitative conversion. N-oxides may be more active than their corresponding tertiary amines or less active. Whilst N-oxides are easily reduced to their corresponding tertiary amines by chemical means, in the human body this happens to varying degrees. Some N-oxides undergo nearly quantitative reductive conversion to the corresponding tertiary amines, in other cases the conversion is a mere trace reaction or even completely absent. (M.H. Bickel: "The pharmacology and Biochemistry of N-oxides", Pharmaco-loaical Reviews, 21(4), 325 - 355, 1969).
Preferred compounds of the invention are compounds having formula (I) wherein m is 1, n is 2, 3, 4 or 5, x is 1, R2 is 4-fluoro or 4-trifluoromethyl, R3 and independently represent hydrogen or methyl, group Q is chosen from structural fragments A, D, F or N, y is 1, and R, is branched or unbranched alkoxy(C,_3), and tautomers, stereoisomers a nd N -oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
It has been found that the compounds according to the invention show high affinity fo r both the dopamine D2 receptor and the serotonin reuptake site. The compounds show activity as antagonists at dopamine D2 receptors as they potentially antagonize apomorphine-induced climbing behaviour in mice. The compounds also show activity as inhibitors of serotonin reuptake, as they potentiate 5-HTP induced behaviour in mice. The compounds are active in therapeutic models sensitive to clinically relevant antipsychotics (e.g. the conditioned avoidance response; Van der Heyden &
Bradford, Behav. Brain Res., 1988, 31:61-67) and antidepressants or anxiolytics (e.g.
suppression of stress-induced vocalization; van der Poel et al., Psycho-pharmacology, 1989, 97: 147-148). In contrast to clinically relevant dopamine D2 receptor antagonists the described compounds have a low propensity to induce catalepsy in rodents and as such are likely to induce less extrapyramidal side effects than existing antipsychotic agents. The inhibitory activity of serotonin reuptake inherent in these compounds may be responsible for the therapeutic effects observed in behavioural models sensitive to either antidepressants or anxiolytics. The compounds can be used for the treatment of affections or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotonergic systems, for example: aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition or memory, Parkinson's disease, and in particular schizophrenia and other psychotic disorders.
GENERAL ASPECTS OF SYNTHESES
The synthesis of all piperazine derivatives in this patent can be performed as depicted in Scheme 1 for the preparation of compound 3.The starting phenyl piperazines can be obtained as described in EP 0 189 612: Hartog, J et aL, 1985:
'New pharmaceutical compositions having a psychtropic activity'; Feenstra, R.W.; de Moes, J.P; Hofma, J.; Kling, H.; Kuipers, W; Long, S.K.; Tulp, M.T.M.; Van der Heyden, J.A.M and Kruse, C.G.; 'New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2 receptor and serotonin receptor affinities. Bioorg. & Med. Chem. Lett., 2001, 11, 2345-2349 and WO
01/14330. The alkylphenone derivatives 2 are commercially available.
Scheme 1 a % ~ ~x O
I \ J 1 a (NJ ~N) O
Bradford, Behav. Brain Res., 1988, 31:61-67) and antidepressants or anxiolytics (e.g.
suppression of stress-induced vocalization; van der Poel et al., Psycho-pharmacology, 1989, 97: 147-148). In contrast to clinically relevant dopamine D2 receptor antagonists the described compounds have a low propensity to induce catalepsy in rodents and as such are likely to induce less extrapyramidal side effects than existing antipsychotic agents. The inhibitory activity of serotonin reuptake inherent in these compounds may be responsible for the therapeutic effects observed in behavioural models sensitive to either antidepressants or anxiolytics. The compounds can be used for the treatment of affections or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotonergic systems, for example: aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition or memory, Parkinson's disease, and in particular schizophrenia and other psychotic disorders.
GENERAL ASPECTS OF SYNTHESES
The synthesis of all piperazine derivatives in this patent can be performed as depicted in Scheme 1 for the preparation of compound 3.The starting phenyl piperazines can be obtained as described in EP 0 189 612: Hartog, J et aL, 1985:
'New pharmaceutical compositions having a psychtropic activity'; Feenstra, R.W.; de Moes, J.P; Hofma, J.; Kling, H.; Kuipers, W; Long, S.K.; Tulp, M.T.M.; Van der Heyden, J.A.M and Kruse, C.G.; 'New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2 receptor and serotonin receptor affinities. Bioorg. & Med. Chem. Lett., 2001, 11, 2345-2349 and WO
01/14330. The alkylphenone derivatives 2 are commercially available.
Scheme 1 a % ~ ~x O
I \ J 1 a (NJ ~N) O
5 (N) H 3i 3ii 3 O /-N
a Reagents and conditions: (i) DIPEA, KI, CH 3CN, reflux; ~NH2 (ii) H2NO-CH2CH2NH2 = 2HCI, DIPEA, EtOH, reflux.
The selection of the particular synthetic procedures depends on factors known to those skilled in the art such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
PHARMACEUTICAL PREPARATIONS
The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxillary substances such as liquid or solid carrier material. The pharmaceutical compositions of the invention may be administered enterally, orally, parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders, tablets, capsules (including microcapsuies), ointments (creams or gel) or suppositories. Suitable excipients for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances. Frequently used auxillary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
a Reagents and conditions: (i) DIPEA, KI, CH 3CN, reflux; ~NH2 (ii) H2NO-CH2CH2NH2 = 2HCI, DIPEA, EtOH, reflux.
The selection of the particular synthetic procedures depends on factors known to those skilled in the art such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
PHARMACEUTICAL PREPARATIONS
The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxillary substances such as liquid or solid carrier material. The pharmaceutical compositions of the invention may be administered enterally, orally, parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders, tablets, capsules (including microcapsuies), ointments (creams or gel) or suppositories. Suitable excipients for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances. Frequently used auxillary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
Compounds of the present invention are generally administered as pharmaceutical compositions which are important and novel embodiments of the invention because of the presence of the compounds, more particularly specific compounds disclosed herein. Types of pharmaceutical compositions that may be used include but are not limited to tablets, chewable tablets, capsules, solutions, parenteral solutions, suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention, a pharmaceutical pack or kit is provided comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention. Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
PHARMACOLOGICAL METHODS
In vitro affinity for dopamine-D2 receptors Affinity of the compounds for dopamine -D2 receptor s was determined using the receptor binding assay described by I. Creese, R. Schneider and S.H. Snyder:
"PH]-Spiroperidol labels dopamine receptors in rat pituitary and brain", Eur.J.Pharmacol., 46, 377 - 381, 1977.
In vitro affinity for serotonin reuptake sites Affinity of the compounds for serotonin reuptake sites was determined using the receptor binding assay described by E. Habert et al.,: "Characterisation of (3H]-paroxetine binding to rat cortical membranes", Eur.J.Pharmacol., 118, 107 -114, 1985.
DOSAGES
The affinity of the compounds of the invention for dopamine-D2 receptors and serotonine reuptake sites was determined as described above. From the binding affinity measured for a given compound of formula (1), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured Ki-value, 100% of the receptors likely will be occupied by the compound.
Converting that concentration to mg of compound per kg of patient yields a theoretical lowest effective dose, assuming ideal bioavailability.
Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dosage expediently administered is 0.001 - 1000 mg/kg, preferably 0.1-100 mg/kg of patient's bodyweight.
TREATMENT
The term 'treatment' as used herein refers to any treatment of a mammalian, preferably human condition or disease, and includes: (1) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it, (2) inhibiting the disease or condition, i.e., arresting its development, (3) relievi ng the disease or condition, i.e., causing regression of the condition, or (4) relieving the conditions caused by the disease, i.e., stopping the symptoms of the disease.
The preparation of the compounds having formula (I) will now be described in more detail in the following Examples.
PHARMACOLOGICAL METHODS
In vitro affinity for dopamine-D2 receptors Affinity of the compounds for dopamine -D2 receptor s was determined using the receptor binding assay described by I. Creese, R. Schneider and S.H. Snyder:
"PH]-Spiroperidol labels dopamine receptors in rat pituitary and brain", Eur.J.Pharmacol., 46, 377 - 381, 1977.
In vitro affinity for serotonin reuptake sites Affinity of the compounds for serotonin reuptake sites was determined using the receptor binding assay described by E. Habert et al.,: "Characterisation of (3H]-paroxetine binding to rat cortical membranes", Eur.J.Pharmacol., 118, 107 -114, 1985.
DOSAGES
The affinity of the compounds of the invention for dopamine-D2 receptors and serotonine reuptake sites was determined as described above. From the binding affinity measured for a given compound of formula (1), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured Ki-value, 100% of the receptors likely will be occupied by the compound.
Converting that concentration to mg of compound per kg of patient yields a theoretical lowest effective dose, assuming ideal bioavailability.
Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dosage expediently administered is 0.001 - 1000 mg/kg, preferably 0.1-100 mg/kg of patient's bodyweight.
TREATMENT
The term 'treatment' as used herein refers to any treatment of a mammalian, preferably human condition or disease, and includes: (1) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it, (2) inhibiting the disease or condition, i.e., arresting its development, (3) relievi ng the disease or condition, i.e., causing regression of the condition, or (4) relieving the conditions caused by the disease, i.e., stopping the symptoms of the disease.
The preparation of the compounds having formula (I) will now be described in more detail in the following Examples.
EXAMPLES
EXAMPLE 1: MATERIALS AND METHODS
'H and 13C NMR spectra were recorded on a Bruker Avance DRX600 instrument (600 MHz), Varian UN400 instrument (400 MHz) or on a Varian VXR200 instrument (200 MHz) using DMSO-D6 or CDCI3 as solvents with tetramethylsilane as an internal standard. Chemical shifts are given in ppm (b scale) downfield from tetramethylsilane. Coupling constants (J) are expressed in Hz. Flash chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Column chromatography was performed using silica gel 60 (0.063 -0.200 mm, Merck).
Melting points were recorded on a Buchi B-545 melting point apparatus. Mass spectra were recorded on a Micromass QTOF-2 instrument with MassLynx application software for acquisition and reconstruction of the data. Exact mass measurement was done of the quasimolecular ion [M+H]+.
EXAMPLE 2: SYNTHESES OF SPECIFIC COMPOUNDS
The synthesis of compound 3 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5-yl)-1-piperazine (3i). 15 mmol of piperazine (3i) was suspended in 125 ml of acetonitril and 2 equivalents of diisopropylethyl-amine (DIPEA) was added. After 5 minutes stirring at room temperature, 1 equivalent (15 mmol) of chloro-1-(4-trifluoromethyl-phenyl)-pentane-1-one was added, followed by 1 equivalent of sodium iodide. This mixture was stirred at 80 C for 20 hours.
The solvent was removed by evaporation and the residue dissolved in 100 ml of dichloromethane.
The organic layer was washed with water and dried on magnesium sulphate before evaporation. The residue was purified by column chromatography and this yielded 6.4 mmol of the keto-derivative 3ii which was dissolved in 30 ml of methanol.
To this solution 1 equivalent of O-(2-aminoethyl)-hydroxylamine di-HCI salt was added and this mixture was heated for 12 hours at 80 C. After evaporation of the solvent, the residue was dissolved in dichloromethane and washed with water. Drying of the organic layer, using magnesium sulphate and evaporation of the solvent yielded a residue that was purified by column chromatography. The tri HCI -salt of compound 3 was obtained after adding 3 equivalents of HCI in Ethanol to the purified substance.
mp.156-60 C; overall yield 15%.
EXAMPLE 1: MATERIALS AND METHODS
'H and 13C NMR spectra were recorded on a Bruker Avance DRX600 instrument (600 MHz), Varian UN400 instrument (400 MHz) or on a Varian VXR200 instrument (200 MHz) using DMSO-D6 or CDCI3 as solvents with tetramethylsilane as an internal standard. Chemical shifts are given in ppm (b scale) downfield from tetramethylsilane. Coupling constants (J) are expressed in Hz. Flash chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Column chromatography was performed using silica gel 60 (0.063 -0.200 mm, Merck).
Melting points were recorded on a Buchi B-545 melting point apparatus. Mass spectra were recorded on a Micromass QTOF-2 instrument with MassLynx application software for acquisition and reconstruction of the data. Exact mass measurement was done of the quasimolecular ion [M+H]+.
EXAMPLE 2: SYNTHESES OF SPECIFIC COMPOUNDS
The synthesis of compound 3 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5-yl)-1-piperazine (3i). 15 mmol of piperazine (3i) was suspended in 125 ml of acetonitril and 2 equivalents of diisopropylethyl-amine (DIPEA) was added. After 5 minutes stirring at room temperature, 1 equivalent (15 mmol) of chloro-1-(4-trifluoromethyl-phenyl)-pentane-1-one was added, followed by 1 equivalent of sodium iodide. This mixture was stirred at 80 C for 20 hours.
The solvent was removed by evaporation and the residue dissolved in 100 ml of dichloromethane.
The organic layer was washed with water and dried on magnesium sulphate before evaporation. The residue was purified by column chromatography and this yielded 6.4 mmol of the keto-derivative 3ii which was dissolved in 30 ml of methanol.
To this solution 1 equivalent of O-(2-aminoethyl)-hydroxylamine di-HCI salt was added and this mixture was heated for 12 hours at 80 C. After evaporation of the solvent, the residue was dissolved in dichloromethane and washed with water. Drying of the organic layer, using magnesium sulphate and evaporation of the solvent yielded a residue that was purified by column chromatography. The tri HCI -salt of compound 3 was obtained after adding 3 equivalents of HCI in Ethanol to the purified substance.
mp.156-60 C; overall yield 15%.
The synthesis of compound 7 is a 2-step reaction starting from 2-isopropyloxy-phenylpiperazine (7i). 4.2 mmol of phenyl piperazine 7i was suspended in 40 ml acetonitril. Added were 2 eq. of DIPEA, 1 eq. of 4-chloro-1-(4-trifluoromethyl-phenyl)-butane-1-one and 1 eq. potassium iodide. This mixture was refluxed overnight and the solvent evaporated the next day. The residue was purified by column chromatography, yielding 2.5 mmol of the pure keto-compound 7ii, which was dissolved again in 30 ml of ethanol (100%). Added was 1 eq. of O-(2-aminoethyl) hydroxylamine di-HCI salt and 1 eq. of pyridine. This mixture was heated at 80 C for 4 hours. After solvent evaporation the residue was purified by column chromatography and this yielded 2 mmol of an orange oil. The oily substance was dissolved in ethanol and added was 1 eq. of fumaric acid. The amorph fumaric salt of compound 7 was obtained after evaporation; overall yield 50%
The synthesis of compound 8 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5 yl)-1-piperazine (3i). 3.5 mmol of phenyl piperazine (3i) was suspended in 40 ml acetonitril. Added were 2 eq. of DIPEA, 1 eq. of 6-chloro-1-(4-trifluoromethyl-phenyl)-hexane-1-one and 1 eq. potassium iodide. This mixture was refluxed overnight and the solvent evaporated the next day. The residue was purified by column chromatography, yielding 1.7 mmol of the pure keto -compound 8ii, which was dissolved again in 10 ml of ethanol (100%). Added was 1 eq. of O-(2-aminoethyl) hydroxylamine di HCI salt and this mixture was heated at 80 C for hours. After solvent evaporation the residue was purified by column chromatography and this yielded 1.6 mmol of an yellow oil. The oily substance was dissolved in ethanol and added was 2 eq. of fumaric acid. The amorph fumaric salt of compound 8 was obtained after evaporation; overall yield 45%.
The synthesis of compound 9 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5-yl)-1-piperazine. Compound 3ii (30 mmol) was dissolved in 20 ml of methanol. To this solution, 1 equivalent of O-(N-methyl-2-aminoethyl)-hydroxylamine di-HCI salt was added and this mixture was heated for 5 hours at 80 C. After evaporation of the solvent, the residue was dissolved in dichloromethane and washed with sodium bicarbonate solution and followed by brine. The organic layer was dried by using magnesium sulphate and evaporation of the solvent yielded a residue that was purified by column chromatography. The fumaric-sait of the compound 9 was obtained after adding an ethanolic solution of 1 equivalents of fumaric acid to the purified substance followed by evaporation of the solvent;
overall yield 15%.
The synthesis of compound 10 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5-yl)-1-piperazine (3i). 6 mmol of phenyl piperazine 3i was suspended in 40 ml acetonitril. Added were 2 eq. of DIPEA, 1 eq. of 7-chloro-l-(4-5 trifluoromethyl-phenyl)-heptane-1-one and 1 eq. potassium iodide. This mixture was refluxed overnight and the solvent evaporated the next day. The residue was purified by column chromato-graphy, yielding 4.2 mmol of the pure keto-compound 1011, which was dissolved again in 25 ml of ethanol (100%). Added was 1 eq. of O-(2-aminoethyl) hydroxylamine di-HCI salt and this mixture was heated at 80 C for 10 hours. After solvent evaporation the residue was purified by column chromatography and this yielded 2 mmol of an yellowy oil. The oily substance was dissolved in ethanol and added was 1.5 eq. of fumaric acid. The amorph fumaric salt of compound 10 was obtained after evaporation; overall yield 35%.
Table 1. Compounds of the general formula (1) I
N Q
R~
a N
n m 0 N
~ (1) (R2)x wherein Q can be one of the structural fragments A-N
O, 0) O~OH
A H B C D
II I ~ N~O ~
E
F G N
O
\O
O
(P70~ I O CI ) ~ H K
H (R,) N O N O
/
~ L ~ M N
cpnd y R, Q x R2 R3 R4 n m mp ( C) 4 1 2-OMe N 1 4-F H H 2 1 150-152 7 1 OCH(Me)2 N 1 4-CF3 H H 2 1 amorph 8 - - A 1 4-CF3 H H 4 1 amorph 9 - - A 1 4-CF3 Me H 3 1 amorph - - A 1 4-CF3 H H 5 1 amorph 11 1 2-OMe N 1 4-CF3 H H 5 1 amorph The specific compounds of which the synthesis is descri bed above are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict 5 the scope of the invention in any way. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is thus intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the claims.
EXAMPLE 3: FORMULATION OF COMP. 3 USED IN ANIMAL STUDIES
For oral (p.o.) administration : to the desired quantity (0.5-5 mg) of the solid compound 3 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose in water and 2% (v/v) of Poloxamer 188 (Lutrol F68), the compound was suspended by vortexing for 10 minutes. The pH was adjusted to 7 with a few drops of aqueous NaOH (0.1N). Remaining particles in the suspension were further suspended by using an ultrasonic bath.
For intraperitoneal (i.p.) administration: to the desired quantity (0.5-15 mg) of the solid compound 3 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose and 5% mannitol in water, the compound was suspended by vortexing for 10 minutes. Finally the pH was adjusted to 7.
EXAMPLE 4: PHARMACOLOGICAL TESTRESULTS
Dopamine-D2 and serotonin reuptake receptor affinity data obtained according to the protocols given above are shown in the table below.
The synthesis of compound 8 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5 yl)-1-piperazine (3i). 3.5 mmol of phenyl piperazine (3i) was suspended in 40 ml acetonitril. Added were 2 eq. of DIPEA, 1 eq. of 6-chloro-1-(4-trifluoromethyl-phenyl)-hexane-1-one and 1 eq. potassium iodide. This mixture was refluxed overnight and the solvent evaporated the next day. The residue was purified by column chromatography, yielding 1.7 mmol of the pure keto -compound 8ii, which was dissolved again in 10 ml of ethanol (100%). Added was 1 eq. of O-(2-aminoethyl) hydroxylamine di HCI salt and this mixture was heated at 80 C for hours. After solvent evaporation the residue was purified by column chromatography and this yielded 1.6 mmol of an yellow oil. The oily substance was dissolved in ethanol and added was 2 eq. of fumaric acid. The amorph fumaric salt of compound 8 was obtained after evaporation; overall yield 45%.
The synthesis of compound 9 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5-yl)-1-piperazine. Compound 3ii (30 mmol) was dissolved in 20 ml of methanol. To this solution, 1 equivalent of O-(N-methyl-2-aminoethyl)-hydroxylamine di-HCI salt was added and this mixture was heated for 5 hours at 80 C. After evaporation of the solvent, the residue was dissolved in dichloromethane and washed with sodium bicarbonate solution and followed by brine. The organic layer was dried by using magnesium sulphate and evaporation of the solvent yielded a residue that was purified by column chromatography. The fumaric-sait of the compound 9 was obtained after adding an ethanolic solution of 1 equivalents of fumaric acid to the purified substance followed by evaporation of the solvent;
overall yield 15%.
The synthesis of compound 10 is a 2-step reaction starting from 4-(2,3 dihydro-1,4 benzodioxin-5-yl)-1-piperazine (3i). 6 mmol of phenyl piperazine 3i was suspended in 40 ml acetonitril. Added were 2 eq. of DIPEA, 1 eq. of 7-chloro-l-(4-5 trifluoromethyl-phenyl)-heptane-1-one and 1 eq. potassium iodide. This mixture was refluxed overnight and the solvent evaporated the next day. The residue was purified by column chromato-graphy, yielding 4.2 mmol of the pure keto-compound 1011, which was dissolved again in 25 ml of ethanol (100%). Added was 1 eq. of O-(2-aminoethyl) hydroxylamine di-HCI salt and this mixture was heated at 80 C for 10 hours. After solvent evaporation the residue was purified by column chromatography and this yielded 2 mmol of an yellowy oil. The oily substance was dissolved in ethanol and added was 1.5 eq. of fumaric acid. The amorph fumaric salt of compound 10 was obtained after evaporation; overall yield 35%.
Table 1. Compounds of the general formula (1) I
N Q
R~
a N
n m 0 N
~ (1) (R2)x wherein Q can be one of the structural fragments A-N
O, 0) O~OH
A H B C D
II I ~ N~O ~
E
F G N
O
\O
O
(P70~ I O CI ) ~ H K
H (R,) N O N O
/
~ L ~ M N
cpnd y R, Q x R2 R3 R4 n m mp ( C) 4 1 2-OMe N 1 4-F H H 2 1 150-152 7 1 OCH(Me)2 N 1 4-CF3 H H 2 1 amorph 8 - - A 1 4-CF3 H H 4 1 amorph 9 - - A 1 4-CF3 Me H 3 1 amorph - - A 1 4-CF3 H H 5 1 amorph 11 1 2-OMe N 1 4-CF3 H H 5 1 amorph The specific compounds of which the synthesis is descri bed above are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict 5 the scope of the invention in any way. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is thus intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the claims.
EXAMPLE 3: FORMULATION OF COMP. 3 USED IN ANIMAL STUDIES
For oral (p.o.) administration : to the desired quantity (0.5-5 mg) of the solid compound 3 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose in water and 2% (v/v) of Poloxamer 188 (Lutrol F68), the compound was suspended by vortexing for 10 minutes. The pH was adjusted to 7 with a few drops of aqueous NaOH (0.1N). Remaining particles in the suspension were further suspended by using an ultrasonic bath.
For intraperitoneal (i.p.) administration: to the desired quantity (0.5-15 mg) of the solid compound 3 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose and 5% mannitol in water, the compound was suspended by vortexing for 10 minutes. Finally the pH was adjusted to 7.
EXAMPLE 4: PHARMACOLOGICAL TESTRESULTS
Dopamine-D2 and serotonin reuptake receptor affinity data obtained according to the protocols given above are shown in the table below.
Table 2. In vitro affinities of compounds of the invention In vitro affinity Dopamine-D2 5-HT reuptake cpnd pK, pK, 3 8.3 8.2 4 8.6 7.3 8.2 8.3 6 6.6 8.3 7 8.1 7.0 8 8.3 8.0 9 8.4 7.5 8.4 8.5 11 8.3 8.3
Claims (10)
1. Compounds of the general formula (1):
wherein:
- m and n independently are either 1, 2, 3, 4, 5, 6, 7 or 8, - x is 0, 1, 2 or 3 - R2 is halogen, branched or unbranched alkyl(C1-6), phenyl, benzyl, branched or unbranched alkoxy(C1-6), trifluoromethyl or cyano - R3 and R4 independently represent hydrogen, alkyl(C1-6), phenyl, benzyl or acetyl - group Q is chosen from structural fragments A-N
wherein:
- y is 1, 2 or 3 - R1 is halogen, branched or unbranched alkyl(C1-6), phenyl, benzyl, branched or unbranched alkoxy(C1-6), trifluoromethyl or cyano, and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
wherein:
- m and n independently are either 1, 2, 3, 4, 5, 6, 7 or 8, - x is 0, 1, 2 or 3 - R2 is halogen, branched or unbranched alkyl(C1-6), phenyl, benzyl, branched or unbranched alkoxy(C1-6), trifluoromethyl or cyano - R3 and R4 independently represent hydrogen, alkyl(C1-6), phenyl, benzyl or acetyl - group Q is chosen from structural fragments A-N
wherein:
- y is 1, 2 or 3 - R1 is halogen, branched or unbranched alkyl(C1-6), phenyl, benzyl, branched or unbranched alkoxy(C1-6), trifluoromethyl or cyano, and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
2. Compounds as claimed in claim 1 of general formula (1) wherein m is 1, n is 2, 3, 4 or 5, x is 1, R2 is 4-fluoro or 4-trifluoromethyl, R3 and R4 independently represent hydrogen or methyl, group Q is chosen from structural fragments A, D, F or N, y is 1, R1 is branched or unbranched alkoxy(C1-3), and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
3. A compound as claimed in claim 1, selected from the group:
wherein the symbols represent those in formula (1):
and the structural fragments A, D, F or N:
and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
wherein the symbols represent those in formula (1):
and the structural fragments A, D, F or N:
and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
4. A pharmaceutical composition comprising, in addition to a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance, a pharmacologically active amount of at least one compound of one of the claims 1-3, or a salt thereof, as an active ingredient.
5. A method of preparing a composition as claimed in claim 4, characterised in that at least one compound of one of the claims 1 -3, or a salt thereof, is brought into a form suitable for administration.
6. A compound as claimed in any of the claims 1 -3, or a salt thereof, for use as a medicament
7. Use of a compound as claimed in any of the claims 1-3 for the preparation of a pharmaceutical composition for the treatment of CNS disorders.
8. Use as claimed in claim 7, characterized in that said disorders are aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition or memory, Parkinson's disease, schizophrenia and other psychotic disorders.
9. Use as claimed in claim 7, characterized in that said disorder is depression.
10. Use as claimed in claim 7, characterized in that said disorders are schizophrenia and other psychotic disorders.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63344904P | 2004-12-07 | 2004-12-07 | |
EP04106350 | 2004-12-07 | ||
US60/633,449 | 2004-12-07 | ||
EP04106350.4 | 2004-12-07 | ||
PCT/EP2005/056500 WO2006061372A2 (en) | 2004-12-07 | 2005-12-06 | Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2587928A1 true CA2587928A1 (en) | 2006-06-15 |
Family
ID=34930004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002587928A Abandoned CA2587928A1 (en) | 2004-12-07 | 2005-12-06 | Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1828161A2 (en) |
JP (1) | JP2008523026A (en) |
KR (1) | KR20070091646A (en) |
CN (1) | CN101072765A (en) |
AR (1) | AR052258A1 (en) |
AU (1) | AU2005313386A1 (en) |
BR (1) | BRPI0518370A2 (en) |
CA (1) | CA2587928A1 (en) |
MX (1) | MX2007006756A (en) |
RU (1) | RU2007125636A (en) |
SA (1) | SA05260389B1 (en) |
TW (1) | TW200633987A (en) |
WO (1) | WO2006061372A2 (en) |
ZA (1) | ZA200704151B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
US8063062B2 (en) | 2006-12-20 | 2011-11-22 | Solvay Pharmaceuticals B.V. | Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition |
US8138174B2 (en) | 2007-01-10 | 2012-03-20 | Solvay Pharmaceuticals B.V. | Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition |
EA200970672A1 (en) * | 2007-01-10 | 2010-02-26 | Солвей Фармасьютикалс Б.В. | CONNECTIONS WITH THE COMBINATION OF CANNABINOID-SWANTAGONISM AND INHIBITION OF SEROTONIN REVERSE CAPTURE |
CN101918382A (en) * | 2008-01-15 | 2010-12-15 | 雅培卫生保健产品有限责任公司 | Bifeprunox derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2162312B1 (en) * | 1971-12-10 | 1975-02-07 | Buzas Andre | |
EP0189612B1 (en) * | 1984-12-21 | 1992-11-04 | Duphar International Research B.V | New pharmaceutical compositions having a psychotropic activity |
AU772189B2 (en) * | 1999-08-23 | 2004-04-08 | Solvay Pharmaceuticals B.V. | New phenylpiperazines |
AR032712A1 (en) * | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | A MESILATE OF PHENYLPIPERAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT |
-
2005
- 2005-12-06 JP JP2007544892A patent/JP2008523026A/en not_active Withdrawn
- 2005-12-06 MX MX2007006756A patent/MX2007006756A/en unknown
- 2005-12-06 RU RU2007125636/04A patent/RU2007125636A/en not_active Application Discontinuation
- 2005-12-06 CA CA002587928A patent/CA2587928A1/en not_active Abandoned
- 2005-12-06 CN CNA2005800420702A patent/CN101072765A/en active Pending
- 2005-12-06 SA SA05260389A patent/SA05260389B1/en unknown
- 2005-12-06 AR ARP050105090A patent/AR052258A1/en not_active Application Discontinuation
- 2005-12-06 KR KR1020077015625A patent/KR20070091646A/en not_active Application Discontinuation
- 2005-12-06 AU AU2005313386A patent/AU2005313386A1/en not_active Abandoned
- 2005-12-06 EP EP05819231A patent/EP1828161A2/en not_active Withdrawn
- 2005-12-06 WO PCT/EP2005/056500 patent/WO2006061372A2/en active Application Filing
- 2005-12-06 TW TW094142933A patent/TW200633987A/en unknown
- 2005-12-06 BR BRPI0518370-7A patent/BRPI0518370A2/en not_active IP Right Cessation
-
2007
- 2007-05-22 ZA ZA200704151A patent/ZA200704151B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200633987A (en) | 2006-10-01 |
ZA200704151B (en) | 2008-08-27 |
MX2007006756A (en) | 2007-11-09 |
AU2005313386A1 (en) | 2006-06-15 |
JP2008523026A (en) | 2008-07-03 |
AR052258A1 (en) | 2007-03-07 |
RU2007125636A (en) | 2009-01-20 |
SA05260389B1 (en) | 2009-06-09 |
KR20070091646A (en) | 2007-09-11 |
BRPI0518370A2 (en) | 2008-11-18 |
WO2006061372A2 (en) | 2006-06-15 |
EP1828161A2 (en) | 2007-09-05 |
WO2006061372A3 (en) | 2006-11-23 |
CN101072765A (en) | 2007-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8101619B2 (en) | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | |
JP2008523031A (en) | Phenylpiperazine derivatives exhibiting a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | |
CA2587928A1 (en) | Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites | |
EP1824486B1 (en) | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites | |
US20060122175A1 (en) | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | |
ZA200609447B (en) | Substituted cyclic urea derivatives | |
US20060122177A1 (en) | Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | |
EP1828168A2 (en) | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites | |
US7371769B2 (en) | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | |
MX2007006817A (en) | Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition. | |
US20070142397A2 (en) | Phenypiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |